A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：FUTURE VIROLOGY ISSN： 1746-0794 出版频率： Bimonthly 出版社： FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB   出版社网址： http://www.futuremedicine.com/ 期刊网址： http://www.futuremedicine.com/loi/fvl 影响因子： 0.431(2008) 主题范畴： VIROLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Mankind has been at the mercy of viral diseases for millennia. However, advances in virologic research are occuring at an unprecedented rate. In particular, the fields of virology and genomic research have been closely linked for many years; the first whole genome to be sequenced was viral in origin 鈥縝acteriophage phi X174, in 1977. Since then, many more viral genomes have been mapped, and with the human genome also available, it is now possible to determine viral鈥揾ost interactions during infection in a unprecedented level of detail. This has consequently provided a complete catalogue of potential antiviral targets to be investigated. The emergence of pandemic HIV led to a dramatic increase in research in the field of rational drug design, resulting in the large number of antiviral drugs and vaccines entering clinical trials today. Furthermore, the very features and mechanisms of viruses that make them such a threat to humankind are also now being manipulated and utilized in the burgeoning field of gene therapy. Viral vectors are being used to efficiently deliver and express therapeutic genes for the treatment of a variety of conditions, including cancer. Viral vectors are also vital tools for the study of functional genomics, using, for example, viral-induced gene silencing. In addition, viruses poses a threat as potential agents of bioterrorism in cases where no natural immunity exists in the population. This is the case for viral diseases such as smallpox. The development of drug-resistant mutants and the emergence of new viruses (such as SARS coronavirus and novel influenza strains with pandemic potential) are adding additional burdens to the already time-constrained virology community. The need to move swiftly in the event of a new disease outbreak makes it essential for the virologist to keep up-to-date with all key advances. Future Virolgy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, provideing an authoritative but accessible forum for this ever-expanding area of research. Coverage includes: The molecular basis of viral diseases Virus鈥揾ost interactions Overviews highlighting optimal therapeutic and diagnostic approaches, along with potential future options Summaries evaluating newly approved antiviral agents Adverse events and drug safety Pharmacoeconomics and cost鈥揵enefit issues in virology New and re-emerging viruses DNA microarrays for the identification of new viruses Epidemiologic studies and trends The problem of viral drug resistance, and potential methods to overcome this Vaccine development and the prevention of viral diseases The use of viral vectors in gene therapy and functional genomics Defense against the use of viruses in bioterrorism Indexing Impact Factor: 0.431 (2008) Chemical Abstracts EMBASE/Excerpta Medica CAPCAS EMBiology Science Citation Index Expanded (SciSearch庐) Journal Citation Reports/Science Edition Scopus Instructions to Authors fmauthorguidelinesforweb.pdf Editorial Board Akira S, Osaka University, Japan Barnard DL, Utah State University, USA Dr. Dale Barnard received his Ph.D. in 1987 from Brigham Young University in microbiology with an emphasis in virology.  He completed a one-year post-doctorate in the Antiviral Program at Utah State University, after which he was appointed Research Associate Professor in the Department of Animal, Dairy and Veterinary Sciences at Utah State University. He is currently the head of the Biochemical, Emerging Virus, and Veterinary Virology Sections of the Institute for Antiviral Research at Utah State University. Dr. Barnard鈥檚 current research interests include discovery of chemotherapeutics for inhibition of severe acute respiratory syndrome-associated coronavirus and rhinoviruses and elucidation of mechanisms of action of antiviral therapies. Buckheit RW, ImQuest BioSciences, Inc., USA Compans R, Emory University, USA Conway B, University of British Columbia, Canada Cullen BR, Duke University Medical Center, USA Dr. Cullen received his master鈥檚 degree in virology from the University of Birmingham, England. After emigrating to the United States, he worked as a research technician before reentering graduate school at the University of Medicine and Dentistry of New Jersey, where he received his Ph.D. degree in microbiology in 1984. Dr. Cullen then studied retroviral gene regulation as a member of the Department of Molecular Genetics at Hoffmann-La Roche. Dr. Cullen joined the faculty at Duke University Medical Center in 1987 where he is currently James B. Duke Professor in the Department of Molecular Genetics and Microbiology and Director of the Center for Virology. De Clercq E, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium Erik De Clercq was born in Dendermonde, Belgium, on March 28, 1941. He received his M.D. degree in 1966 and his Ph.D. in 1972 both at the Katholieke Universiteit Leuven (K.U.Leuven) in Belgium. After having spent two years at Stanford University Medical School as a postdoctoral fellow, he returned to the K.U. Leuven Medical School, where he became docent (assistant professor) in 1973, professor in 1975, and full professor in 1977. As of today he is teaching the courses of Cell Biology, Biochemistry, Microbiology and Virology in the first, second and third undergraduate years of the Medical School at the K.U. Leuven and K.U. Leuven Campus Kortrijk. Prof. E. De Clercq served as chairman of the Department of Microbiology from 1986-1991. Since 1999 he is serving once more as chairman of the Department of Microbiology and Immunology. In 1985, he became President of the Rega Foundation and, in 1986, Chairman of the Directory Board of the Rega Institute for Medical Research, two positions which he still holds. He is a titular member of the Belgian Royal Academy of Medicine and the Academia Europaea, and has also held the Prof. P. De Somer Chair of Microbiology at the K.U.Leuven. Prof. De Clercq鈥檚 scientific achievements are in the antiviral chemotherapy field, and, in particular, the development of new antiviral agents for the treatment of various viral infections, including AIDS. He has (co)-discovered a number of antiviral drugs, currently used in the treatment of various virus infections, such as herpes simplex (valaciclovir), herpes zoster (brivudin), AIDS (stavudine), CMV (cytomegalovirus) infections (cidofovir), HBV (hepatitis B virus) infections (adefovir), and HIV infections (AIDS) (tenofovir disoproxil fumarate, marketed as VireadTM, and, in combination with emtricitabine, as TruvadaTM). Desselberger U, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy Est茅 JA, Fundaci贸 IrsiCaixa, Spain Field HJ, University of  Cambridge, UK Hugh Field is Reader in Comparative Virology at the Centre for Veterinary Science, Cambridge University. He obtained his BSc with first class honours in microbiology from London University in 1969 and the PhD from Bristol in 1972 where he first became interested in the comparative biology of the herpesviruses. He moved to Cambridge in 1976 to join the late Professor Peter Wildy and he won the Pfizer Academic Award in Biology in 1984 and  obtained the Cambridge University MA followed by the ScD in 1996. He is a Fellow of the Royal College of Pathologists and Fellow of Queens' College, Cambridge where he is also Director of Studies in Medical and Veterinary Sciences. His research field is the development and assessment of antiviral compounds. His studies have focused on laboratory infection models to investigate the effects of antiviral agents on the pathogenesis of human and animal herpesviruses especially involving neurological infections including latency. He is the author of some 250 articles in these and related areas; presently focusing on the development of resistance to helicase/primase inhibitors of herpes simplex virus. He was for many years a member of the Board of Directors of the International Society for Antiviral Research and was elected President of the Society from 1994 to 1996. He was founding editor for the journals Antiviral Chemistry and Chemotherapy and the former, International Antiviral News. He is currently editor-in-chief of Antiviral Chemistry and Chemotherapy and a virology editor of the Journal of Antimicrobial Chemotherapy, as well as serving on the Editorial Boards of several other virology journals. Currently, he is much involved with undergraduate teaching as organiser and lecturer in courses on infectious disease. Fujinami RS, University of Utah, USA Gallo RC, University of Maryland Baltimore, USA Grossberg SE, Medical College of Wisconsin, USA Sidney E. Grossberg is Professor of Microbiology and Molecular Genetics as well as Professor of Internal Medicine at the Medical College of Wisconsin. Professor Grossberg received his M.D. degree at Emory University. Following post-graduate training at the Duke University and Johns Hopkins University Schools of Medicine, he held faculty positions at the University of Minnesota Medical School and Cornell University Medical College. At the Medical College of Wisconsin he was Chairman of the Department of Microbiology from 1966 to 1997, and held the Walter Schroeder Professorship of Microbiology. He spent sabbatical years in Paris at the Pasteur Institute, first with the Nobel Laureate Andr茅 Lwoff and subsequently with Luc Montagnier. His major focus of research has been on the induction and actions of the interferons, and he has contributed to studies on influenza viruses, arthropod-borne viruses, and retroviruses. Dr. Grossberg has received an NIH Research Career Development Award and has been designated a Markle Scholar, American Cancer Society Scholar in Cancer Research, and Senior Fellow of the European Molecular Biology Organization, as well as a Fellow of the American Academy of Microbiology and of the American Association for the Advancement of Science. He has been the Secretary-Treasurer of the American Society for Virology since 1984, and in 2001 the Society established the annual Sidney E. Grossberg Lectureship. Harrich D, Queensland Institute of Medical Research, Australia Hayden FG, University of Virginia, USA Hirsch H, University of Basel, Switzerland Ikuta K, Research Institute for Microbial Diseases, Osaka University, Japan Katze MG, University of Washington, USA Michael G Katze is a professor of microbiology and the Associate Director and Core Staff Scientist at the Washington National Primate Research Center, USA. Research in the Katze laboratory is focused on the varied and complex mechanisms used by viruses to avoid the interferon-mediated antiviral response and the clever means by which viruses hijack the cellular protein synthesizing machinery. The laboratory is a leader in using the technologies of functional genomics, including DNA microarrays and proteomics, to study the wide constellation of changes in cellular gene expression and protein production that occur in response to virus infection. The laboratory is also working to develop a nationwide resource to facilitate the use of genomic technologies in nonhuman primate research, with particular emphasis on the rhesus macaque. Killington R, University of Leeds, UK Professor Dick Killington completed both his BSc and PhD degrees in Microbiology at the University Of Birmingham, UK. His post-doctoral position at the MRC Clinical Research Centre, Harrow, introduced him to virology research, where he studied the structure and replication of rhinoviruses. In 1972 he took up a lecturing position at the University of Leeds and began a 25 year period of research into the diversity and host-virus interactions of the herpesviruses. More recently Dick has returned to picornavirus research, with a particular interest in virus attachment. Dick has been a member of the Society for General Microbiology Virus Group, past UK Editor of Archives of Virology, and until recently was Head of the School of Biochemistry and Microbiology at the University of Leeds. He is co-author of three Microbiology textbooks. Dick is currently Head of the Infection and Immunity Group in the Institute of Molecular and Cellular Biology at the University of Leeds. Knipe DM, Harvard Medical School, USA Korba BE, Georgetown University Medical Center, USA Leib DA, Washington University School of Medicine, USA Nelson JA, Vaccine & Gene Therapy Institute, Oregon Health & Science University, USA Openshaw PJM, Imperial College London, UK Peter Openshaw qualified in medicine in 1979, and completed his PhD Immunology in 1988 (Brigitte Askonas FRS, NIMR, Mill Hill) studying respiratory syncytial virus infections in mice. He is now Head of the Academic Department of Respiratory Medicine at St Mary鈥檚, Professor of Experimental Medicine, Imperial College London and Head, Section of Respiratory Infections at the National Heart and Lung Institute, London UK. His research interests include common colds, the role to T-cells in the pathogenesis of lung disease, viral effects on T-cell subset differentiation and the relationship of viral infections in childhood with the development of wheezing disorders. He is an honorary Physician at St. Mary's Hospital, Paddington. He is a member of the Council of the British Society for Immunology and a Fellow of the Academy of Medical Sciences, UK. Peterlin BM, University of California San Francisco, USA Matija Peterlin is Professor of Medicine, Microbiology and Immunology at the University of California, San Francisco. A native of Slovenia, he received his medical degree from Harvard University and pursued clinical and research studies at Stanford University and the National Institutes of Health before joining the faculty at UCSF in 1981. For 18 years, he was also an Investigator of the Howard Hughes Medical Institute. During this time, his research interests have been in acquired and congenital immunodeficiencies. His studies of HIV revealed how the virus replicates productively and how it establishes proviral latency in the host. Thus, he defined mechanisms of action of NF-kappaB and the regulatory Tat protein of HIV. These studies impacted greatly on how the elongation of RNA polymerase II is controlled in cells. Moreover, he elucidated the mechanism of action of viral accessory proteins Nef and Vif. These studies have impacted the fields of cellular trafficking and the formation of multivesicular bodies as well as RNA and DNA editing. In congenital immunodeficiences, Dr. Peterlin defined lesions in the bare lymphocyte syndrome (BLS), where the absence of MHC class II determinants on B cells leads to the severe combined immunodeficiency in affected children. BLS can result from mutations in four different transcription factors, one of which, the class II transactivator (CIITA) is the master regulator of genes required for antigen processing and presentation by the MHC class II pathway. Introducing CIITA into most somatic cells renders them antigen presenting cells. Applications of these studies find resonance in new small animal models of autoimmunity, immunotherapy of cancer and vaccination. These efforts resulted in over 150 peer reviewed publications, 30 reviews and several honors, such as the Humboldt Prize, honorary professorship at the U. of Ljubljana and membership in the Slovenian Academy of Arts and Sciences. Polyak SJ, University of Washington, USA Dr. Stephen Polyak is a Research Associate Professor in the Department of Laboratory Medicine at the University of Washington in Seattle.  He also holds adjunct appointments in the Departments of Microbiology and Pathobiology.  Dr. Polyak received his Ph.D. in Molecular Virology and Immunology at McMaster University, Hamilton, Ontario, Canada, in 1993. Dr. Polyak was appointed to the faculty in February of 2000. Dr. Polyak鈥檚 research focuses on the interactions between liver cells and hepatitis C virus (HCV), a global health problem.  The laboratory focuses on innate antiviral responses to HCV, as well as countermeasures used by HCV to thwart the cellular response to virus infection.  Dr. Polyak is the author of over 40 publications, reviews and book chapters.  He was a former recipient of a Liver Scholar Award from the American Liver Foundation, and currently is supported by NIAID, NIDDK and NIAAA.  He is a reviewer and editorial board member for several virology and hepatology journals, a member of study sections nationally (NIH) and internationally (Canadian Institutes for Health Research), and a former and current member of the AASLD Basic Research Committee and Membership Committee, respectively. Rice AP, Baylor College of Medicine, USA Dr. Andrew P. Rice received his Ph.D. from Brandeis University and carried out Postdoctoral training at the Imperial Cancer Research Fund in London. He was a Staff Scientist at Cold Spring Harbor Laboratories and has been at Baylor College of Medicine since 1990, where he is a Professor in the Department of Molecular Virology and Microbiology. Dr. Rice has investigated the interaction between viruses and the host cell since his graduate studies. His current research focuses on HIV infection and cellular factors that mediate viral replication. Richman DD, University of California San Diego, USA Dr. Richman is Professor of Pathology and Medicine at the University of California San Diego (UCSD) and the Florence Seeley Riford Chair in AIDS Research. He is Director of the Research Center for AIDS and HIV Infection at the VA San Diego Healthcare System and Director of the Center for AIDS Research at UCSD. He trained as an infectious disease physician and medical virologist at Stanford, the NIH and Harvard before joining the faculty at UCSD in 1976. He has focused his investigation on HIV disease and pathogenesis for the past 20 years. His laboratory was the first to identify HIV drug resistance. The lab joined two others in identifying latently infected CD4 cells as the obstacle to eradication of HIV with potent antiretroviral therapy. Recently his lab described the dynamics of the neutralizing antibody response to HIV and the rapidity of viral escape and evolution in response to this selective pressure. Rossi JJ, Beckman Research Institute of the City of Hope, USA Rowlands DJ, University of Leeds, UK Secrist JA, Southern Research Institute, USA Schubert U, University of Erlangen-Nuremberg, Germany Stebbing J, Imperial College of Medicine, London, UK Stevenson M, University of Massachusetts, USA Tscharke DC, The Australian National University, Australia David Tscharke is an NHMRC R. Douglas Wright Fellow and Senior Lecturer in the School of Biochemistry and Molecular Biology at The Australian National University (Canberra, Australia).  Since his PhD (1997, University of Adelaide) working on the CD8+ T-cell response to neural herpes simplex virus infection, his attention has turned to vaccinia virus pathogenesis and immunology.  He has worked with Prof. Geoffrey L Smith, FRS in the UK and then Drs Jonathon Yewdell and Jack Bennink at the US NIH. Since returning to Australia in 2003 he has held an NHMRC Howard Florey Centenary Fellowship at the Queensland Institute of Medical Research in Brisbane and moved to the ANU in 2006.  He mapped the first CD8+ T-cell epitopes for poxviruses in mice and his ongoing work uses vaccinia virus as a model for understanding T-cell immunity to virus infections.  Zack J, UCLA, USA Zoulim F, INSERM, France